Hot Investment Trends in Pharma and Healthcare Segments

Investment Research

The Pharma and Healthcare segments are undergoing constant changes. Post pandemic, there has been an increase in traction for investment in the pharmaceutical industry. Investors are slowly gaining the confidence that was shaken due to the pandemic.

Compared to the investments in 2019, there has been a steady rise in healthcare investments, especially in biopharma and health technology, closely followed by diagnostics. The healthcare investment trend is expected to continue in 2022 as travel has begun and sectors are moving back to normalcy.

The M&A deals, on the other hand, remained unaffected during the pandemic and there were substantial deals that were signed during the peak pandemic phase.

Key Highlights:

  • Oncology was and remains the most lucrative investment segment in 2022. While major activities are being noticed in the healthcare space, oncology has ranked highest with major deals across the globe.
  • Non-invasive patient monitoring and neurology registered high deals in 2021. Rapid diagnostic kits and AI-enabled tech for rapid screening emerged as major segments and continue to attract the attention of investors.
  • In 2022, the pharma segment is targeting $1.7 trillion in deals. The year will be ruled by the top names in pharma and devices who will be targeting small players in the east.

To know more...


Related Topics

SGA Whitepaper - The impact of elevated inflation on US insurance companies

White Papers

The Impact of Elevated Inflation on US Insurance Companies

The US inflation is on a rising trend post the COVID-19 pandemic, driven by commodity shock and supply disruption. This elevated inflation remains a cause...

SG Analytics Industry Insights

White Papers

SG Analytics Industry Insights Global Fintech Sector Update...

Our latest report examines how fintech companies are innovating methods to improve profitability with markets and economies opening up again after the...

We bring comprehensive data driven insights to everyone, everywhere